X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Glenmark Pharma Fact Sheet, Glenmark Pharma Financial Results - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Glenmark Pharma Fact Sheet   (GLPH)

Here is the latest financial fact sheet of Glenmark Pharma. For more details, see the Glenmark Pharma quarterly results and Glenmark Pharma share price and chart. For a sector overview, read our pharmaceuticals sector report.

GLENMARK PHARMA Price History

Price Rs 559.1
Mkt Cap Rs m 151,659
Vol '000 29.0
P/E X 16.6
P/CF X 13.7
EPS (TTM) Rs 33.7
% ch % -0.7
No. of shares m 271.28
% ch week % -3.8
% ch 1-mth % -12.0
% ch 12-mth % 5.3
52 week H/L Rs 711.6/483.6
(As on May 24, 2019 (Close))
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

GLENMARK PHARMA Financials

No. of Mths
Year Ending
12
Mar-14
*
12
Mar-15
*
12
Mar-16
*
12
Mar-17
*
12
Mar-18
*
5-Yr Chart
Click to enlarge
GLENMARK PHARMA EQUITY SHARE DATA
High Rs6128791,262993930 
Low Rs464752672729517 
Sales per share (Unadj.) Rs221.4244.4271.1325.5322.6 
Earnings per share (Unadj.) Rs20.117.526.339.328.5 
Diluted earnings per shareRs20.117.527.440.929.6 
Cash flow per share (Unadj.) Rs28.127.134.648.739.2 
Dividends per share (Unadj.) Rs2.002.002.002.002.00 
Adj. dividends per shareRs2.002.002.082.082.08 
Dividend yield (eoy) %0.40.20.20.20.3 
Book value per share (Unadj.) Rs110.086.1128.6159.2183.0 
Adj. book value per shareRs110.086.1133.8165.6190.3 
Shares outstanding (eoy) m271.22271.29282.16282.17282.17 
Bonus/Rights/Conversions  ---ESOP- 
Price / Sales ratio x2.43.33.62.62.2 
Avg P/E ratio x26.746.636.721.925.4 
P/CF ratio (eoy) x19.130.127.917.718.5 
Price / Book Value ratio x4.99.57.55.44.0 
Dividend payout %9.911.47.65.17.0 
Avg Mkt Cap Rs m145,889221,284272,778242,991204,206 
No. of employees `000NA9.510.013.013.7 
Total wages/salary Rs m10,26212,02413,78216,40818,718 
Avg. sales/employee Rs ThNM6,961.17,630.57,083.96,636.8 
Avg. wages/employee Rs ThNM1,262.51,374.81,265.41,364.7 
Avg. net profit/employee Rs ThNM499.0741.2855.1586.1 
GLENMARK PHARMA INCOME DATA
Net Sales Rs m60,05266,29876,49691,85791,031 
Other income Rs m115219200374914 
Total revenues Rs m60,16766,51676,69692,23091,945 
Gross profit Rs m10,90810,22514,37220,36716,154 
Depreciation Rs m2,1682,6002,3432,6443,019 
Interest Rs m1,8861,9021,7892,3732,856 
Profit before tax Rs m6,9695,94310,44015,72411,193 
Minority Interest Rs m00000 
Prior Period Items Rs m00000 
Extraordinary Inc (Exp) Rs m000-8100 
Tax Rs m1,5131,1903,0093,8273,155 
Profit after tax Rs m5,4564,7527,43011,0888,039 
Gross profit margin %18.215.418.822.217.7 
Effective tax rate %21.720.028.824.328.2 
Net profit margin %9.17.29.712.18.8 
GLENMARK PHARMA BALANCE SHEET DATA
Current assets Rs m47,62753,19959,04368,74669,887 
Current liabilities Rs m29,49237,11139,99327,02732,879 
Net working cap to sales %30.224.324.945.440.7 
Current ratio x1.61.41.52.52.1 
Inventory Days Days5770758581 
Debtors Days Days1311381199693 
Net fixed assets Rs m30,35717,44521,41624,13228,892 
Share capital Rs m271271282282282 
"Free" reserves Rs m21,41523,08636,01444,64351,353 
Net worth Rs m29,83323,35736,29644,92551,635 
Long term debt Rs m24,28725,74424,87345,36341,418 
Total assets Rs m86,33687,429101,929117,639125,954 
Interest coverage x4.74.16.87.64.9 
Debt to equity ratio x0.81.10.71.00.8 
Sales to assets ratio x0.70.80.80.80.7 
Return on assets %8.57.69.011.48.6 
Return on equity %18.320.320.524.715.6 
Return on capital %16.416.020.019.115.1 
Exports to sales %11.744.843.200 
Imports to sales %1.07.17.400 
Exports (fob) Rs m7,03929,72033,04400 
Imports (cif) Rs m5794,6805,67200 
Fx inflow Rs m8,52831,29936,94556,15236,317 
Fx outflow Rs m3,64110,85661,0668,0849,720 
Net fx Rs m4,88820,443-24,12248,06826,598 
GLENMARK PHARMA CASH FLOW
From Operations Rs m 8,537 4,817 3,449 6,574 16,481 
From Investments Rs m -3,681 -5,400 -8,802 -7,124 -10,133 
From Financial Activity Rs m -980 1,992 6,986 5,432 -4,685 
Net Cashflow Rs m 1,896 -311 934 1,992 1,770 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 48.3%
Foreign collaborators 0.0%
Indian inst/Mut Fund 6.9%
FIIs 34.4%
ADR/GDR 0.0%
Free float 10.5%
Shareholders 56,727
Pledged promoter(s) holding 0.0%
 

Company Information

REGD OFF B/2, Mahalaxmi Chambers, 22, Bhulabhai Desai Road, Mumbai - 400 026
E-MAIL complianceofficer@glenmarkpharma.com WEB www.glenmarkpharma.com
TELEPHONE (022) 4018 9999 FAX (022) 4018 9986
SECTOR PHARMACEUTICALS GROUP MISCELLANEOUS
TR AGENT Karvy Computer, 17-24, Vithalrao Nagar, Madhapur, Hyderabad-81
AUDITOR Walker, Chandiok & Co.
CHM: Glenn Saldanha (MD) COMP SEC: Sanjay Kumar Chowdhary YEAR OF INC: 1977 BSE CODE: 532296 FV (Rs): 1 DIV YIELD (%): 0.4

Read: GLENMARK PHARMA 2017-18 Annual Report Analysis

More Pharmaceuticals Company Fact Sheets:   FULFORD INDIA  DR. REDDYS LAB  ALKEM LABORATORIES  J.B.CHEMICALS  ELDER PHARMA  

Compare GLENMARK PHARMA With:   FULFORD INDIA  DR. REDDYS LAB  ALKEM LABORATORIES  J.B.CHEMICALS  ELDER PHARMA  

Compare GLENMARK PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Modi's Victory Creates Sensex History; Ache Din Ahead?(Podcast)

Throughout the week, one slogan that took over the market and country as a whole was, Ab ki baar phir Modi Sarkar.

Views on news

GLENMARK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 11.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, GLENMARK PHARMA has posted a net profit of Rs 1 bn (up 11.1% YoY). Sales on the other hand came in at Rs 26 bn (up 15.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of GLENMARK PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, GLENMARK PHARMA has posted a net profit of Rs 4 bn (up 93.3% YoY). Sales on the other hand came in at Rs 26 bn (up 14.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

More Views on News

Most Popular

My Top 7 Stocks to Profit from Sensex 100,000(The 5 Minute Wrapup)

May 16, 2019

Tanushree Banerjee explains everything you need to know about the Rebirth of India and Sensex 100,000.

3 Stocks to Bet on to Become a 'Dividend Millionaire'(Profit Hunter)

May 14, 2019

As markets continue to rattle amid earning season, upcoming elections, volatile crude price and US China trade war, it's a great idea to add some stability to your portfolio by adding dividend stocks.

Indian Steel: The Perfect Multibagger Opportunity(Profit Hunter)

May 17, 2019

A structurally strong Indian Steel Industry will help India achieve 8%+ GDP growth in the coming years.

What Makes TVS Srichakra and CCL Products a Cut Above the Rest?(The 5 Minute Wrapup)

May 17, 2019

Despite the commodity nature of their businesses, these two stocks have rewarded shareholders well.

The Bitter Pill that Will Lay the Foundation for Sensex 100,000(The 5 Minute Wrapup)

May 14, 2019

These companies will help the Sensex more than double from current levels.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 8-QTR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS